Ca2+ signalling in fibroblasts and the therapeutic potential of KCa 3.1 channel blockers in fibrotic diseases.
The role of Ca2+ signalling in fibroblast physiology is of great interest, particularly in fibrosis-related diseases. Intracellular free Ca2+ ([Ca2+ ]i ) in mammalian cells is a ubiquitous secondary messenger, regulating a number of cellular functions such as secretion, metabolism, differentiation, proliferation and contraction. The intermediate conductance Ca2+ -activated K+ channel KCa 3.1 is pivotal in Ca2+ signalling and plays a central role in fibroblast processes including cell activation, migration and proliferation through the regulation of cell membrane potential. Evidence gleaned through a number of approaches demonstrates that KCa 3.1 plays an important role in the development of many fibrotic diseases, including idiopathic pulmonary fibrosis, renal tubulointerstitial fibrosis due to several causes, and cardiovascular disease. The selective KCa 3.1 blocker senicapoc was well tolerated in human clinical trials for sickle cell disease, raising the possibility of rapid translation to the clinic for people suffering from pathological tissue fibrosis. This review is a comprehensive analysis of the data suggesting that targeting KCa 3.1 should be a high priority for human fibrotic disease.